title: How patients experience and manage dryness and irritation from acne treatment.
abstract: BACKGROUND
  Products that may cause irritation are widely used to treat acne. Irritation has the potential to reduce treatment adherence. How patients manage irritation and dryness is not well characterized.
  
  
  OBJECTIVE
  To study self-reported irritation, its impact and coping mechanisms in patients who had been treated for acne with a clindamycin-5% benzoyl peroxide (BPO) product.
  
  
  METHODS
  An Internet-based survey of 200 subjects, aged 15-40 years who had used a clindamycin-5% BPO fixed combination product in the last six months on at least 50 percent of their face, at least five days per week.
  
  
  RESULTS
  The majority of subjects (57%) had moderate acne, 28 percent had severe acne. Bothersome side effects of the clindamycin-5% BPO combination included dry skin (55%), flaky/peeling skin (45%), irritated skin (44%), itchy skin (39%) and redness (37%). As a result, subjects used the product only as a spot treatment (33%), only when breakouts seemed worse (28%), or less often than recommended (32%); stopped using from time to time (32%); switched to a different prescription medication and/or an over-the-counter acne product (28%); or stopped using altogether (10%). 41 percent of subjects reported using moisturizers to counteract dryness and redness.
  
  
  CONCLUSIONS
  We queried patients concerning use of combination clindamycin/BPO products and not other products.
  
  
  CONCLUSIONS
  Irritation to clindamycin-5% BPO is a common problem that reduces patients' use of the medication. Strategies to improve treatment include communication with patients on possible side effects, providing written instruction on how to manage irritation and dryness and consideration of alternative topical treatments and treatment regimens.
authors.affiliation: Center for Dermatology Research, Departments of Dermatology, Pathology and Public Health Sciences, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA. sfeldman@wfubmc.edu
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
authors.forename: Diana M
authors.initials: DM
authors.lastname: Chen
mesh_terms: D000152:Acne Vulgaris / Q000188:drug therapy* / Q000473:pathology; D000279:Administration, Cutaneous; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001585:Benzoyl Peroxide / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002981:Clindamycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003625:Data Collection; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006801:Humans; D020407:Internet; D008297:Male; D055118:Medication Adherence; D012720:Severity of Illness Index; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D003879:Dermatologic Agents; D004338:Drug Combinations; C466951:clindamycin phosphate benzoyl peroxide combination; D002981:Clindamycin; D001585:Benzoyl Peroxide